Evan Wuthrick
0000-0002-0838-9634
Publication & Citation Trends
Publications
0 total
Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.
Cited by 0
Semantic Scholar
First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort
Cited by 0
Semantic Scholar
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial
Cited by 0
Semantic Scholar
Embracing the Future of Clinical Trials in Radiotherapy: An NRG Oncology CIRO Technology Retreat Whitepaper on Pioneering Technologies and AI-Driven Solutions.
Cited by 5
Semantic Scholar
1346 Molecular and immunologic correlates of response in a phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma
Cited by 0
Semantic Scholar
A phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma.
Cited by 0
Semantic Scholar
Real-World Use of Nivolumab plus Relatlimab in the Multi-Modal Management of Melanoma Brain Metastases
Cited by 0
Semantic Scholar
LBA56 ECOG-ACRIN EA6174: STAMP: Surgically treated adjuvant merkel cell carcinoma with pembrolizumab, a phase III trial
Cited by 2
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(25)
Colorectal Cancer Surgical Treatments
(22)
Gastric Cancer Management and Outcomes
(19)
Advanced Radiotherapy Techniques
(15)
Melanoma and MAPK Pathways
(15)
Affiliations
Novartis (Switzerland)
The University of Texas MD Anderson Cancer Center
Thomas Jefferson University
Bristol-Myers Squibb (Germany)
Regeneron (United States)